Histologic Mimics of Basal Cell Carcinoma.
CLINICAL FEATURES AND COURSE
Typically, BCC arises on sun-exposed parts of the body, such as the face, neck, and head, with the remainder on the trunk and lower limbs. (3) Patients are usually middle aged or elderly. (4) Although these slow-growing tumors rarely metastasize, delayed or incomplete treatment may result in significant morbidity from local invasion leading to destruction of skin and deeper tissues, including cartilage and bone, especially in relation to the nares, eyes, and ears. (2) Treatment of BCC can be surgical or nonsurgical. Surgical techniques range from curettage and cautery to cryosurgery, excision, and Mohs micrographic surgery. Photodynamic therapy and topical treatments, such as fluorouracil and imiquimod, have been investigated for superficial lesions. (3,4) Metastatic or locally advanced tumors may be managed with vismodegib or other inhibitors of Hedgehog pathway signaling. (5)
Increased risk of BCC may occur in the setting of certain inherited syndromes. The key role for the sonic hedgehog (SHH) signaling pathway in BCC is highlighted by Gorlin-Goltz syndrome (basal cell nevus syndrome), an autosomal-dominant condition related to germline patched 1 (PTCH1) mutation, characterized by multiple BCCs with a young age of onset, keratocystic odontogenic tumors, medulloblastoma, cardiac and ovarian fibromas, and other skeletal anomalies. (6) Other tumor syndromes that predispose patients to BCC are associated with decreased skin pigmentation or epidermal genomic instability, including xeroderma pigmentosa, Rombo syndrome, Bazex-Christol-Dupre syndrome, Rasmussen syndrome, and albinism. (2)
Microscopically, BCC is composed of cells with large, elongated nuclei that display variably prominent palisading at the edge of tumor nodules (Figure 1, A). Cytoplasm may be inconspicuous, pale, or lightly eosinophilic. Mitoses and single-cell apoptoses are usually present and may be prominent. Intratumoral mucin may form large pools or cystic spaces (Figure 1, B). The BCCs display characteristic clefting between the stroma and edges of tumor nodules, which may be extensive or focal (Figure 1, B). They are associated with a characteristic myxoinflammatory stroma that displays variable proportions of mucin, lymphocytic inflammation, prominent fibroblasts, and collagen thickening (Figure 1, A through C).
Basal cell carcinoma displays a variety of growth patterns that may be broadly divided into nonaggressive (indolent) and aggressive types. Growth patterns exist on a histologic continuum, and combinations of growth patterns in a tumor are seen in 40% to 75% of BCC specimens. (7,8) Furthermore, there is an intrinsic error rate of shave and punch biopsies of approximately 20% in determining BCC subtype classification compared with complete excisions. (8) Despite those limitations, growth patterns represent a major predictor of tumor behavior. (2)
Indolent BCC variants, such as superficial and nodular (or circumscribed) BCCs, show small lobules extending into the papillary dermis from the basal layer of the epidermis or large nodules in the papillary and reticular dermis, respectively (Figure 1, A and B). Cleft retraction, peripheral palisading, and stromal mucin are often prominent. (2,9)
Aggressive-growth BCC variants, including micronodular, infiltrative, morpheaform, and metatypical, share features of increased cell necrosis, mitotic activity, and stromal proliferation, with a decreased demonstration of stromal retraction, deeper growth, and less circumscription. These variants demonstrate higher rates of recurrence and metastasis (although metastasis is rare for BCC of any growth pattern). (10,11) The infiltrative (or aggressive) growth pattern comprises angulated nests and strands of tumor cells in a prominent, fibroblastic stroma (Figure 1, D). Micronodular BCC shows round to oval tumor nests, but unlike nodular BCC, the nests are smaller and widely dispersed (Figure 1, E). Morpheaform or sclerosing BCC shows thin columns and small nodules associated with intensely collagenized stroma (Figure 1, F). Metatypical BCC has a component of squamous differentiation within angulated nests of tumor cells, imparting morphologic overlap with squamous cell carcinoma. Of note, the term basosquamous carcinoma is sometimes used synonymously for metatypical BCC but may also describe collision tumors between BCC and squamous cell carcinoma; therefore, this term is best accompanied by clarification of the intended definition.
The BCCs may display alternative differentiation, most commonly squamous differentiation. Although many BCCs display focal squamatization, tumors with more-extensive squamous differentiation may be designated as metatypical or keratotic. The metatypical pattern of squamous differentiation is described above. Keratotic BCC demonstrates central squamous differentiation and horn cysts within well-circumscribed basaloid nodules. Less-common forms of alternative/divergent differentiation in BCC include matrical, eccrine, sebaceous, or myoepithelial differentiation. Further variant morphologies that may be seen in BCC include clear cell change, signet ring cells, granular cells, adamantinomatoids, adenoid cystic, and metaplastic (carcinosarcoma). (4)
An additional variant, the fibroepithelioma of Pinkus, typically presents as a solitary nodule on the trunk. Histologically, the tumor is characterized by a well-circumscribed nodule of anastomosing epithelial strands and basaloid buds in a myxoid stroma (Figure 1, G and H). Some have proposed this tumor may represent a fenestrated trichoblastoma. (4) However, the immunophenotypic overlap with BCC, (12,13) and the association with a component of conventional BCC in some cases, (4) support classification as a variant of BCC.
Basal cell carcinoma displays a profile of cytokeratin expression similar to follicular germinative cells, characterized by CK5/6 and CK14 expression and the absence of CK20. (4,14) Reports have been mixed regarding CK7 expression in BCC. (14,15) Ber-EP4 typically shows strong expression. (4) There is diffuse nuclear expression of p63. (16) Epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) are typically not expressed, although EMA expression may be present in squamatized areas. (4,17)
Most BCCs harbor SHH pathway-activating mutations affecting genes, including PTCH1 (the most common aberration), SMO, and SUFU. (18,19) Sporadic BCCs frequently also harbor mutations in the tumor-suppressor TP53. (18,20) Recent studies have identified additional, less-common mutations affecting genes, including MYCN, ERBB2, PIK3CA, NRAS, KRAS, HRAS, PTPN14, and RB1, which may contribute to BCC tumorigenesis in a few cases. (19,21,22)
There are multiple benign and malignant dermatologic entities that may mimic BCC histologically, and misdiagnosis may lead to unnecessary excision or delayed workup of metastatic disease. Histologic mimics of BCC may include nonneoplastic processes (such as follicular induction over dermatofibromas), benign adnexal tumors (especially follicular tumors), or cutaneous carcinomas with basaloid or blue-cell features. Distinguishing these entities requires clinical correlation, identification of key histologic features, and possibly, ancillary tests, including immunohistochemistry. Here, we review situations in which BCCs may show significant histologic overlap with benign and malignant cutaneous lesions and provide a practical approach to distinguishing these entities.
Follicular Induction over Dermatofibroma
The epidermis above a dermatofibroma (DF) may be associated with epidermal hyperplasia, including basaloid proliferations with evidence of follicular differentiation, such as follicular bulbs, dermal papillae, and papillary mesenchymal bodies. (23) These types of proliferation are referred to as follicular induction (FI) (also known as follicular basal cell hyperplasia, (24) epidermal basaloid cell hyperplasia (25) and basaloid epidermal proliferation). (26,27) Estimates of the incidence of FI in dermatofibromas range from 2% to 23%. (24,25,28,29,30) In contrast, the occurrence of BCC over DF is extremely rare, with few supporting case reports. (31-37)
Distinction between FI and BCC can be challenging in superficial biopsies, in which the DF is not directly visualized (Table). Both BCC and FI show peripheral palisading (24) and a superficial, budlike growth pattern (Figure 2, A through C). Cleft retraction can be seen in both, although extensive clefting is more typical of BCC. (24,25,38) In contrast to BCC, FI may demonstrate evidence of follicular differentiation, including germinative buds and papillary mesenchymal bodies (Figure 2, C). (24) One study (24) suggested that clear cell hyperplasia is indicative of FI. Unlike FI, BCC lacks epidermal hyperplasia between nests. (23) Cytologically, FI lacks enlarged, crowded atypical nuclei; increased mitotic figures; or apoptotic bodies. (26) In challenging cases, immunohistochemistry may be considered. Studies have had mixed results regarding the utility of Ki-67 and p53 for distinguishing BCC from FI. (25,28,39-41) Similar to benign follicular tumors, FI will demonstrate colonization by [CK20.sup.+] Merkel cells in most cases, whereas BCC will not. (27,42,43) As noted above, collision tumors between BCC and DF are exceedingly rare; however, the occurrence of FI in this context may represent a potential diagnostic confounder (Figure 2, D through F).
Benign, Hair-Germ Tumors (Trichoepithelioma and Trichoblastoma)
The benign, hair-germ tumors trichoblastoma (TB) and trichoepithelioma (TE) most commonly arise on the head and neck. Some consider TE to represent a subtype of TB. (4) Most TEs are sporadic and solitary tumors in younger patients; however, less commonly, they can be a manifestation of Brooke-Spiegler syndrome, associated with germline mutations in the tumor suppressor gene CYLD. (44,45)
Histologically, TB is a large, circumscribed dermal tumor without epidermal connection, composed of small basaloid cells arrayed in numerous large nodules or micronodules (Figure 3, A). (46-48) Similarly, TE is a well-circumscribed dermal tumor consisting of nests and strands of basaloid cells in a racemiform configuration. Constituent cells in TE appear relatively less primitive than those in TB. The TE may display intermingled horn cysts and epidermal connection in some cases (Figure 3, B). (4) Both TE and TB display peripheral palisading, as well as a follicular stroma characterized by orderly, concentric collagen and fine-spindled fibroblasts, arranged in parallel to the periphery of tumor nodules. Papillary mesenchymal bodies (oval condensations of stroma cupped by tumor epithelium) (Figure 3, C) are highly specific for benign, hair-germ tumors but may not be identified in some cases. Although mucin may be present within tumor nodules, stromal mucin is lacking. Unlike BCC, TE/TB lack prominent cleft retraction, myxoinflammatory stroma, significant mitotic activity, cytologic atypia, or tumor necrosis (Table).
Desmoplastic trichoepithelioma (DTE) is a histologic variant of TE that merits additional description. Typically, DTE presents as a firm plaque or nodule with a central dell on the face of young to middle-aged individuals. Histologically, DTE is characterized by thin cords of small basaloid cells in a densely sclerotic stroma (Figure 3, D). (49-51) Morphologically, DTE mimics morpheaform BCC (mBCC), which can be challenging to differentiate, especially in superficial biopsies. Histologic features that favor DTE are architectural symmetry, horn cysts with calcifications, narrow cellular aggregates, giant cell reactions, and follicular/sebaceous/infundibular differentiation (Table). Additionally, the lack of features such as mitotic figures, cytologic atypia, and tumor-to-stroma clefting also favors the diagnosis of DTE, rather than mBCC. (49,52-54)
In challenging cases, immunohistochemical stains can be helpful in discriminating between TE/TB and BCC (Table). Benign, hair-germ tumors are frequently colonized by benign Merkel cells, which can be highlighted by CK20 (Figure 3, E). CK20 can be used in combination with androgen receptor (AR), with positive tumor AR staining and absent CK20 staining supporting BCC, whereas [CK20.sup.+] colonizing Merkel cells and lack of AR support a benign diagnosis. (54-56) Several limitations of the AR/CK20 panel should be kept in mind. The AR expression is often focal and sometimes completely absent in BCC. Some TEs/TBs have a low density of colonizing Merkel cells, which may require serial sections for detection. In addition, Merkel cells in a background of vellus follicles may simulate tumor colonization. (57)
Multiple additional markers have been investigated to aid in this distinction. BCL2 has been reported to have diffuse staining in BCC and peripheral staining of TE/TB; however, several studies have found this stain to have limited specificity and sensitivity, especially in the setting of DTE. (58-64) CD10 is more likely to display stromal expression in TE/TB and tumor expression in BCC. (54,63,65-67) A similar pattern of tumor expression in BCC and stromal expression in TE/TB has been proposed for CD34, but some reports have not found this stain diagnostically useful. (61,64,68,69) Although p75NTR is more likely to show diffuse expression in DTE than in mBCC, (70) a later study (71) demonstrated limited specificity, with diffuse expression in 36% of mBCC and 44% of microcystic adnexal carcinomas. In recent studies, strong and diffuse expression of PHLDA1 (TDAG51), a follicular stem-cell marker, has been shown to be highly specific for TE/TB, (53,55,72) although expression in micronodular BCC has been reported. (72)
In summary, although markers, including AR, CK20, and PHLDA1, may be useful in distinguishing BCC from benign, hair-germ tumors, no single marker appears completely sensitive or specific for this distinction. Furthermore, it is likely that hair-germ tumors exist on a spectrum with BCC. (4) Hence, clinical and histopathologic findings remain critical for guiding diagnosis and management.
Basaloid Follicular Hamartoma
Basaloid follicular hamartoma (BFH) is a benign tumor of follicular infundibular/isthmus origin, which may be hereditary, acquired, or congenital. (73) Clinically, BFH may present as a solitary lesion; a small, linearly arranged group; or a generalized distribution of tan to brown papules or plaques. (48) The finding of generalized BFHs should prompt further investigation to rule out nevoid BCC syndrome, Cowden syndrome, generalized follicular hamartoma syndrome, and Rombo syndrome. (73) Histologically, BFH presents as a superficial dermal proliferation of interconnecting strands of basaloid to squamoid cells that connect to the epidermis and contain small, cystic spaces (Figure 4, A and B). (74) There is resemblance to the infundibulocystic variant of BCC (Figure 4, C and D). Unlike BFH, infundibulocystic BCC typically displays at least focal mitotic activity, cytologic atypia, myxoinflammatory stroma, and/or cleft retraction (Table). CD10, CD34, and BCL2 have been proposed to be helpful in this distinction, with staining patterns in BFH similar to those described above for TE/TB. One report described colonizing CK20+ Merkel cells in infundibulocystic BCC as well as in BFH; therefore, there is uncertainty regarding the diagnostic utility of CK20 in this specific context. (75)
Tumor of the Follicular Infundibulum
Tumor of the follicular infundibulum (TFI) most commonly presents as a solitary, keratotic papule or plaque on the face of middle-aged to elderly patients (48,76) or as an eruptive variant in younger patients with nevus sebaceous or certain tumor syndromes. (48,77,78) Histologically, TFI has a distinctive pattern that consists of interconnecting plates of monomorphic keratinocytes arising as an extension from the basal epidermal layer (Figure 5). (48,76-78) Small, abortive follicular structures may connect to the plate from below. Neoplastic cells are pale in comparison to the surrounding normal keratinocytes. (48,76-78) Nuclear palisading is common. (48,76-78) Although TFI may be misinterpreted as superficial BCC, TFI lacks cytologic atypia, myxoinflammatory stroma, peripheral clefting, and significant mitotic activity (Table). (48,76-79) Unlike BCC, TFI displays colonizing CK20+ Merkel cells, and lacks Ber-EP4 staining. (80) Elastin stains may demonstrate an elastin fiber network at the base of the lesion. (48,79,80)
Squamous Cell Carcinoma
Squamous cell carcinoma may be challenging to distinguish from BCC in limited biopsies. Ber-EP4 is commonly employed to assist in this distinction, with strong expression in BCC and absent expression in squamous cell carcinoma (Table). (81,82) Of note, Ber-EP4 may not be expressed in squamatized areas of BCC, (83) and focal staining with Ber-EP4 has been reported in squamous cell carcinoma. (84)
Microcystic Adnexal Carcinoma
Microcystic adnexal carcinoma (MAC) is a rare, locally aggressive, malignant neoplasm with follicular and sweat-gland differentiations. (85-88) Clinically, MAC overlaps with BCC as a light-tan, smooth, firm lesion primarily affecting the central face, head, and neck of adult patients of all ages. (85-87,89) Histologically, MAC is an ill-defined, infiltrative lesion that extends deep in the dermis (Figure 6). (85,86,89) Deceptively bland squamoid and basaloid cells form tubular and ductal structures that are haphazardly distributed in a desmoplastic stroma (Figure 6, B). (85,86,89) Horn cysts, primarily in the superficial portion of the lesion, and eosinophilic secretions within the ductal lumens are frequently identified. (86,87) Mitotic activity is rare to absent. Perineural invasion is common and often a helpful diagnostic finding. (86-88)
Differentiating mBCC and MAC poses a diagnostic challenge to dermatologists and pathologists. Furthermore, syringoma and DTE (described earlier) are 2 benign entities that also display a strandlike growth of tumor cells in sclerotic stroma and, hence, may appear highly similar to mBCC and MAC (Table). Adequate sampling to assess the depth of the lesion and the presence of perineural invasion are crucial because syringoma and DTE are superficial lesions that do not invade nerves. (85,86,89,90) Both MAC and mBCC are ill-defined and infiltrative lesions, although mBCC less frequently invades nerves and consists entirely of basaloid cells that have no ductal differentiation. (85,89,90) Conversely, peripheral palisading, tumor-to-stroma retraction, and myxoinflammatory stroma are rare in MAC. (85,89,90)
Immunohistochemistry is generally not useful to discriminate between MAC and syringoma. (90) Staining with CEA and EMA highlight ductal structures in MAC, which may help differentiate it from DTE and mBCC. (86,90) In addition, CK15 stains positive in MAC and is negative in mBCC. (86,90) Reports are mixed regarding whether a subset of MACs may express Ber-Ep4, (53,91,92) and MACs may express p75NTR. (71)
Sebaceous carcinoma (SC) is a rare, aggressive, malignant neoplasm predominately affecting the periorbital region of elderly patients. (89,93,94) Other anatomic sites that may be affected include the head and neck, trunk, extremities, and genital regions. (95) The rates of distant metastases and death in periocular SC are significantly greater than they are in BCC, and thus, accurate diagnosis is critical. (96) The classic histologic appearance of SC is a dermal-based tumor with lobules of basaloid cells. (90,93,97,98) A variable proportion of neoplastic cells show evidence of sebaceous differentiation in the form of indented nuclei and microvacuolated cytoplasm (Figure 7, A). Sebaceous differentiation may be diminished or absent in high-grade tumors. (89,90,94) Cytologic atypia, nuclear pleomorphism, and mitotic activity are readily identified, (93,97,98) and nuclear palisading may be present. (74)
Although sebocytes and sebaceous ductlike structures have been identified in BCC (Figure 7, B), sebaceous lobular architecture is not observed. (99) Intraepidermal pagetoid spread is common in SC and is absent in BCC. (89,90) Peripheral clefting is typically absent in SC. (89,90)
Immunohistochemical stains EMA and low-molecularweight cytokeratin are strongly expressed in SC, in contrast to the weak-to-absent expression in BCC (Table). (57,89,98,100,101) Although AR displays diffuse expression in SC and focal expression in BCC, Ber-EP4 is typically negative in SC and positive in BCC. Adipophilin and perilipin have been shown to stain strongly in SC and are restricted to sebocytes in BCC with sebaceous differentiation; however, nonspecific staining may be a challenge. (98,102,103)
Merkel Cell Carcinoma
Merkel cell carcinoma (MCC) is a rare, highly aggressive, primary cutaneous neuroendocrine carcinoma affecting older individuals and immunosuppressed patients and often presents as an erythematous or violaceous papule, nodule, or plaque on the skin of the head and neck or extremities. Although less than 1% of malignant skin tumors are MCCs, (104) it is a significant cause of death from skin cancer, with a mortality rate of 30% to 75%.105 About one-third of patients will have metastatic disease at the time of diagnosis. (106) Because of the increased mortality and high metastatic potential of MCC, it must be distinguished from less-aggressive lesions, such as BCC. Prompt staging is critical for establishing prognosis and guiding proper treatment in MCC.
Histologically, MCC typically appears on scanning magnification as a large, dermal, "blue" tumor nodule with sheetlike or trabecular growth (Figure 8, A and B). Nested or infiltrative growth patterns reminiscent of BCC may be observed. (107) Both BCC and MCC may display epidermal connections. However, unlike BCC, MCC may have an intraepidermal component. (108-111) Both MCC and BCC may have focal or extensive squamous differentiation. (105) Peripheral palisading may be identified in a few MCC tumors but is typically focal. (107,112-115) Clefts between aggregates of MCC and adjacent stroma are not infrequently identified in MCC (Figure 8, C). (107) Although increased stromal mucin is typical of BCC, (9) more than 90% of MCC tumors may also have some degree of stromal mucin (Figure 8, C). (107,113) Stromal fibrosis and inflammation may also be present in MCC. (105) However, despite that overlap in stromal features, the classic BCC myxoinflammatory stroma is not observed in MCC.
The distinction between BCC and MCC may be more readily distinguished by cell morphology. Although tumor cells of BCC are characteristically elongated with hyperchromatic nuclei, visible cytoplasm, and scattered mitotic activity and necrosis, tumor cells of MCC have a homogenous salt-and-pepper chromatin pattern, nuclear molding, scant cytoplasm, and abundant mitotic activity and necrosis. (105)
Merkel cell carcinoma cells share antigenic profiles of both epithelial and neuroendocrine cells. They express epithelial markers, such as low-molecular-weight keratins and EMA, as well as neuroendocrine markers, including chromogranin and synaptophysin. (116) Intermediate filaments, such as cytokeratins and neurofilament, classically demonstrate a paranuclear, dotlike pattern of staining in MCC (Figure 8, D), which is not observed in BCC. In some MCC tumors, there is membranous or cytoplasmic cytokeratin staining, with or without paranuclear dots. (105,117) Most MCCs express CK20, whereas that stain is negative in BCC. (114) Merkel cell polyomavirus large T-antigen protein, expressed in approximately 70% to 80% of MCCs, is a highly specific marker for distinguishing MCC from BCC. (118) Chromogranin or synaptophysin are not useful for the differential diagnosis of MCC from BCC because some BCC may express neuroendocrine markers. (119,120) Ber-EP4 is expressed in both BCC and MCC. (105)
OTHER DIAGNOSTIC PITFALLS
Any large basaloid tumor presenting in the dermis, including poorly differentiated adnexal carcinoma or metastatic carcinoma, has the potential to be mistaken for BCC if attention is not given to the clinical presentation, high-grade cytologic atypia, and absence of hallmark features of BCC.
Rare variants of BCC may be associated with specific diagnostic pitfalls. Adenoid BCC may be confused with adenoid cystic carcinoma, in which setting CD117 and CD43 may be useful. (4,121) In addition, BCC with extensive clear cell changes may raise consideration for trichilemmal carcinoma, clear cell melanoma, and other clear cell tumors presenting in the skin. (122) Rarely, BCC may display prominent, thick, fibrous stroma mimicking cylindroma. (4) Matrical differentiation may raise consideration for pilomatrical carcinoma. (4)
We present several benign and malignant mimics of BCC and compare and contrast their clinical and histologic features to BCC. When a tumor is suspected of being a BCC but lacks some hallmark features of BCC or exhibits features not commonly seen in BCC, a differential diagnosis that includes the entities described above should be considered. Immunohistochemistry is helpful in differentiating BCC from its mimics; however, no stain is completely sensitive or specific. Therefore, integration of clinical, morphologic, and immunohistochemical features may be necessary in challenging cases.
(1.) Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. I Am Acad Dermatol. 1994;30(5, pt 1):774-778.
(2.) Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Mod Pathol. 2006;19(suppl 2):S127-147.
(3.) Wong CS, Strange RC, LearJT. Basal cell carcinoma. BMJ. 2003;327(7418): 794-798.
(4.) Kazakov DV, Michal M, Kacerovska D, McKee PH. Lesions with predominant follicular differentiation. In: Kazakov DV, ed. Cutaneous Adnexal Tumors. 1st ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012:173-328.
(5.) Wong SY, Dlugosz AA. Basal cell carcinoma, Hedgehog signaling, and targeted therapeutics: the long and winding road. J Invest Dermatol. 2014; 134(e1):E18-E22.
(6.) Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004;6(6):530-539.
(7.) Sexton M, Jones DB, Maloney ME. Histologic pattern analysis of basal cell carcinoma. Study of a series of 1039 consecutive neoplasms. J Am Acad Dermatol. 1990;23(6, pt 1):1118-1126.
(8.) Russell EB, Carrington PR, Smoller BR. Basal cell carcinoma: a comparison of shave biopsy versus punch biopsy techniques in subtype diagnosis. J Am Acad Dermatol. 1999;41(1):69-71.
(9.) Goltz RW, Fusaro RM, Jarvis J. The carbohydrates in basal cell epitheliomas; a histochemical study. J Invest Dermatol. 1959;32(6):629-640.
(10.) Walling HW, Fosko SW, Geraminejad PA, Whitaker DC, Arpey CJ. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004;23(3-4):389-402.
(11.) Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005; 353(21):2262-2269.
(12.) Sellheyer K, Nelson P, Kutzner H. Fibroepithelioma of Pinkus is a true basal cell carcinoma developing in association with a newly identified tumour-specific type of epidermal hyperplasia. Br J Dermatol. 2012;166(1):88-97.
(13.) Naeyaert JM, Pauwels C, Geerts ML, Verplancke P. CD-34 and Ki-67 staining patterns of basaloid follicular hamartoma are different from those in fibroepithelioma of Pinkus and other variants of basal cell carcinoma. J Cutan Pathol. 2001;28(10):538-541.
(14.) Schirren CG, Rutten A, Kaudewitz P, Diaz C, McClain S, Burgdorf WH. Trichoblastoma and basal cell carcinoma are neoplasms with follicular differentiation sharing the same profile of cytokeratin intermediate filaments. Am J Dermatopathol. 1997;19(4):341-350.
(15.) Yamamoto O, Asahi M. Cytokeratin expression in trichoblastic fibroma (small nodular type trichoblastoma), trichoepithelioma and basal cell carcinoma. Br J Dermatol. 1999;140(1):8-16.
(16.) Park HR, Min SK, Cho HD, Kim KH, Shin HS, Park YE. Expression profiles of p63, p53, survivin, and hTERT in skin tumors. J Cutan Pathol. 2004;31(8):544-549.
(17.) Heyderman E, Graham RM, Chapman DV, Richardson TC, McKee PH. Epithelial markers in primary skin cancer: an immunoperoxidase study of the distribution of epithelial membrane antigen (EMA) and carcinoembryonic antigen (CEA) in 65 primary skin carcinomas. Histopathology. 1984;8(3):423-434.
(18.) de Zwaan SE, Haass NK. Genetics of basal cell carcinoma. Australas J Dermatol. 2010;51(2):81-92; quiz 93-94.
(19.) Bonilla X, Parmentier L, King B, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016; 48(4):398-406.
(20.) Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408(6810):307-310.
(21.) Stacey SN, Sulem P, Masson G, et al. New common variants affecting susceptibility to basal cell carcinoma. Nat Genet. 2009;41(8):909-914.
(22.) Tate G, Kishimoto K, Mitsuya T. Biallelic alterations of the large tumor suppressor 1 (LATS1) gene in infiltrative, but not superficial, basal cell carcinomas in a Japanese patient with nevoid basal cell carcinoma syndrome. Med Mol Morphol. 2015;48(3):177-182.
(23.) Ackerman AB, Reddy VB, Soyer HP. Neoplasms with follicular differentiation. 2nd ed. New York, NY: Ardor Scribendi; 2001. Ackerman's Histologic Diagnosis of Neoplastic Skin Diseases: A Method by Pattern Analysis.
(24.) Cheng L, Amini SB, Tarif Zaim M. Follicular basal cell hyperplasia overlying dermatofibroma. Am J Surg Pathol. 1997;21(6):711-71 8.
(25.) Lindboe CF, Lovdal L. Epidermal basaloid cell hyperplasia overlying dermatofibromas. Am J Dermatopathol. 2011;33(1):52-55.
(26.) Alsaad KO, Obaidat NA, Ghazarian D. Skin adnexal neoplasms--part 1: an approach to tumours of the pilosebaceous unit. J Clin Pathol. 2007;60(2):129-144.
(27.) Mahmoodi M, Asad H, Salim S, Kantor G, Minimo C. Anti-cytokeratin 20 staining of Merkel cells helps differentiate basaloid proliferations overlying dermatofibromas from basal cell carcinoma. J Cutan Pathol. 2005;32(7):491-495.
(28.) Haerslev T, Rossen K, Hou-Jensen K, Jacobsen GK. Immunohistochemical detection of p53 in epidermal proliferations overlying dermatofibromas. Acta Derm Venereol. 1995;75(3):187-189.
(29.) Dalziel K, Marks R. Hair follicle-like change over histiocytomas. Am J Dermatopathol. 1986;8(6):462-466.
(30.) Shuweiter M, Boer A. Spectrum of follicular and sebaceous differentiation induced by dermatofibroma. Am J Dermatopathol. 2009;31(8):778-785.
(31.) Goette DK, Helwig EB. Basal cell carcinomas and basal cell carcinoma-like changes overlying dermatofibromas. Arch Dermatol. 1975;111 (5):589-592.
(32.) Bryant J. Basal cell carcinoma overlying long-standing dermatofibromas. Arch Dermatol. 1977;113(10):1445-1446.
(33.) Buselmeier TJ, Uecker JH. Invasive basal cell carcinoma with metaplastic bone formation associated with a long-standing dermatofibroma. J Cutan Pathol. 1979;6(6):496-500.
(34.) Rotteleur G, Chevallier JM, Piette F, Bergoend H. Basal cell carcinoma overlying histiocytofibroma. Acta Derm Venereol. 1983;63(6):567-569.
(35.) McKenna KE, Somerville JE, Walsh MY, Dawson JF, Burrows D. Basal cell carcinoma occurring in association with dermatofibroma. Dermatology. 1993; 187(1):54-57.
(36.) Curry JL, Goulder SJ, Nickoloff BJ. Occurrence of a basal cell carcinoma and dermatofibroma in a smallpox vaccination scar. Dermatol Surg. 2008;34(1): 132-133; discussion 133-134.
(37.) Cordoba S, Hernandez A, Romero A, et al. Basal cell carcinoma overlying a dermatofibroma [in Spanish]. Actas Dermosifiliogr. 2005;96(9):612-615.
(38.) Rahbari H, Mehregan AH. Adnexal displacement and regression in association with histiocytoma (dermatofibroma). J Cutan Pathol. 1985;12(2):94-102.
(39.) Stashower ME, Smith K, Corbett D, Skelton HG. Basaloid/follicular hyperplasia overlying connective tissue/mesenchymal hamartomas simulating basal cell carcinomas. J Am Acad Dermatol. 2001;45(6):886-891.
(40.) Rossen K, Haerslev T, Hou-Jensen K, Jacobsen GK. Metallothionein expression in basaloid proliferations overlying dermatofibromas and in basal cell carcinomas. Br J Dermatol. 1997;136(1):30-34.
(41.) Han KH, Huh CH, Cho KH. Proliferation and differentiation of the keratinocytes in hyperplastic epidermis overlying dermatofibroma: immunohistochemical characterization. Am J Dermatopathol. 2001;23(2):90-98.
(42.) KanitakisJ, Bourchany D, Faure M, Claudy A. Merkel cells in hyperplastic and neoplastic lesions of the skin: an immunohistochemical study using an antibody to keratin 20. Dermatology. 1998;196(2):208-212.
(43.) Schulz T, Hartschuh W. Merkel cells are absent in basal cell carcinomas but frequently found in trichoblastomas: an immunohistochemical study. J Cutan Pathol. 1997;24(1):14-24.
(44.) du Toit JP, Schneider JW, Visser WI, Jordaan HF. The clinicopathological spectrum of trichoepitheliomas: a retrospective descriptive study. Int J Dermatol. 2016;55(3):270-277.
(45.) Stoica LE, Dascalu RC, Patrascu V, et al. Solitary trichoepithelioma: clinical, dermatoscopic and histopathological findings. Rom J Morphol Embryol. 2015;56(2)(suppl):827-832.
(46.) Pina A, Sauthier P, Rahimi K. Vulvar trichoblastoma: case report and literature review. J Low Genit Tract Dis. 2015;19(1):e10-2.
(47.) Betti R, Alessi E. Nodular trichoblastoma with adamantinoid features. Am J Dermatopathol. 1996;18(2): 192-195.
(48.) Tellechea O, Cardoso JC, ReisJP, et al. Benign follicular tumors. An Bras Dermatol. 2015;90(6):780-796; quiz 797-798.
(49.) Wang Q, Ghimire D, Wang J, et al. Desmoplastic trichoepithelioma: a clinicopathological study of three cases and a review of the literature. Oncol Lett. 2015;10(4):2468-2476.
(50.) Moon SH, Choi HS, Kwon HI, Ko JY, Kim JE. A case of multiple desmoplastic trichoepithelioma. Ann Dermatol. 2016;28(3):411-413.
(51.) Brownstein MH, Shapiro L. Desmoplastic trichoepithelioma. Cancer. 1977;40(6):2979-2986.
(52.) Costache M, Bresch M, Boer A. Desmoplastic trichoepithelioma versus morphoeic basal cell carcinoma: a critical reappraisal of histomorphological and immunohistochemical criteria for differentiation. Histopathology. 2008;52(7): 865-876.
(53.) Sellheyer K, Nelson P, Kutzner H, Patel RM. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers. J Cutan Pathol. 2013;40(4):363-370.
(54.) Astarci HM, Gurbuz GA, Sengul D, Hucumenoglu S, Kocer U, Ustun H. Significance of androgen receptor and CD10 expression in cutaneous basal cell carcinoma and trichoepithelioma. Oncol Lett. 2015;10(6):3466-3470.
(55.) Evangelista MT, North JP. Comparative analysis of cytokeratin 15, TDAG51, cytokeratin 20 and androgen receptor in sclerosing adnexal neoplasms and variants of basal cell carcinoma. J Cutan Pathol. 2015;42(11):824-831.
(56.) Katona TM, Perkins SM, Billings SD. Does the panel of cytokeratin 20 and androgen receptor antibodies differentiate desmoplastic trichoepithelioma from morpheaform/infiltrative basal cell carcinoma? J Cutan Pathol. 2008;35(2):174-179.
(57.) Ferringer T. Immunohistochemistry in dermatopathology. Arch Pathol Lab Med. 2015;139(1):83-105.
(58.) Poniecka AW, Alexis JB. An immunohistochemical study of basal cell carcinoma and trichoepithelioma. Am J Dermatopathol. 1999;21(4):332-336.
(59.) Sabeti S, Malekzad F, Ashayer M, et al. The rate and pattern of bcl-2 and cytokeratin 15 expression in trichoepithelioma and nodular basal cell carcinoma: a comparative study. Indian J Dermatol. 2013;58(5):331-336.
(60.) Smoller BR, Van de Rijn M, Lebrun D, Warnke RA. bcl-2 expression reliably distinguishes trichoepitheliomas from basal cell carcinomas. Br J Dermatol. 1994;131(1):28-31.
(61.) Swanson PE, Fitzpatrick MM, Ritter JH, Glusac EJ, Wick MR. Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens. J Cutan Pathol. 1998;25(3):153-159.
(62.) Verhaegh ME, Arends JW, Majoie IM, Hoekzema R, Neumann HA. Transforming growth factor-beta and bcl-2 distribution patterns distinguish trichoepithelioma from basal cell carcinoma. Dermatol Surg. 1997;23(8):695-700.
(63.) Tebcherani AJ, de Andrade HF Jr, Sotto MN. Diagnostic utility of immunohistochemistry in distinguishing trichoepithelioma and basal cell carcinoma: evaluation using tissue microarray samples. Mod Pathol. 2012; 25(10):1345-1353.
(64.) McNiff JM, Eisen RN, Glusac EJ. Immunohistochemical comparison of cutaneous lymphadenoma, trichoblastoma, and basal cell carcinoma: support for classification of lymphadenoma as a variant of trichoblastoma. J Cutan Pathol. 1999;26(3):119-124.
(65.) Pham TT, Selim MA, BurchetteJLJr, Madden J, Turner J, Herman C. CD10 expression in trichoepithelioma and basal cell carcinoma. J Cutan Pathol. 2006; 33(2):123-128.
(66.) Yada K, Kashima K, Daa T, Kitano S, Fujiwara S, Yokoyama S. Expression of CD10 in basal cell carcinoma. Am J Dermatopathol. 2004;26(6):463-471.
(67.) Cordoba A, Guerrero D, Larrinaga B, Iglesias ME, Arrechea MA, Yanguas JI. Bcl-2 and CD10 expression in the differential diagnosis of trichoblastoma, basal cell carcinoma, and basal cell carcinoma with follicular differentiation. Int J Dermatol. 2009;48(7):713-717.
(68.) Kirchmann TT, Prieto VG, Smoller BR. Use of CD34 in assessing the relationship between stroma and tumor in desmoplastic keratinocytic neoplasms. J Cutan Pathol. 1995;22(5):422-426.
(69.) Ramos-Ceballos FI, Pashaei S, Kincannon JM, Morgan MB, Smoller BR. Bcl-2, CD34 and CD10 expression in basaloid follicular hamartoma, vellus hair hamartoma and neurofollicular hamartoma demonstrate full follicular differentiation. J Cutan Pathol. 2008;35(5):477-483.
(70.) Krahl D, Sellheyer K. p75 Neurotrophin receptor differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma: insights into the histogenesis of adnexal tumours based on embryology and hair follicle biology. Br J Dermatol. 2010;163(1):138-145.
(71.) Jedrych J, McNiff JM. Expression of p75 neurotrophin receptor in desmoplastic trichoepithelioma, infiltrative basal cell carcinoma, and microcystic adnexal carcinoma. Am J Dermatopathol. 2013;35(3):308-315.
(72.) Yeh I, McCalmont TH, LeBoit PE. Differential expression of PHLDA1 (TDAG51) in basal cell carcinoma and trichoepithelioma. Br J Dermatol. 2012; 167(5):1106-1110.
(73.) Mills O, Thomas LB. Basaloid follicular hamartoma. Arch Pathol Lab Med. 2010;134(8):1215-1219.
(74.) Patterson JW. Weedon's Skin Pathology. 4th ed. Amsterdam, the Netherlands: Elsevier; 2015. https://www.clinicalkey.com/#!/browse/book/3-s2.0C20110089780. Accessed March 15, 2017.
(75.) Honarpisheh H, Glusac EJ, Ko CJ. Cytokeratin 20 expression in basaloid follicular hamartoma and infundibulocystic basal cell carcinoma. J Cutan Pathol. 2014;41(12):916-921.
(76.) Kubba A, Batrani M, Taneja A, Jain V. Tumor of follicular infundibulum: an unsuspected cause of macular hypopigmentation. Indian J Dermatol Venereol Leprol. 2014;80(2):141-144.
(77.) Haddad N, Oliveira Filho J, Reis MJ, Michalany AO, Nasser Kda R, Corbett AM. Tumor of follicular infundibulum with unique features. An Bras Dermatol. 2014;89(6):964-966.
(78.) Zhu JW, Zheng M, Lu ZF. Multiple tumors of the follicular infundibulum: a cutaneous reaction pattern? Cutis. 2014;94(6):301-303.
(79.) Kolivras A, Moulonguet I, Ruben BS, Sass U, Cappelletti L, Andre? J. Eruptive tumors of the follicular infundibulum presenting as hypopigmented macules on the buttocks of two black African males. J Cutan Pathol. 2012;39(4): 444-448.
(80.) Alomari A, Subtil A, Owen CE, McNiff JM. Solitary and multiple tumors of follicular infundibulum: a review of 168 cases with emphasis on staining patterns and clinical variants. J Cutan Pathol. 2013;40(6):532-537.
(81.) Kist D, Perkins W, Christ S, Zachary CB. Anti-human epithelial antigen (Ber-EP4) helps define basal cell carcinoma masked by inflammation. Dermatol Surg. 1997;23(11):1067-1070.
(82.) Tellechea O, ReisJP, Domingues JC, Baptista AP. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin. Am J Dermatopathol. 1993;15(5):452-455.
(83.) Yu L, Galan A, McNiff JM. Caveats in BerEP4 stainingto differentiate basal and squamous cell carcinoma. J Cutan Pathol. 2009;36(10):1074-1176.
(84.) Dasgeb B, Mohammadi TM, Mehregan DR. Use of Ber-EP4 and epithelial specific antigen to differentiate clinical simulators of basal cell carcinoma. Biomark Cancer. 2013;5:7-11.
(85.) Cardoso JC, Calonje E. Malignant sweat gland tumours: an update. Histopathology. 2015;67(5):589-606.
(86.) Wetter R, Goldstein GD. Microcystic adnexal carcinoma: a diagnostic and therapeutic challenge. Dermatol Ther. 2008;21(6):452-458.
(87.) Snow S, Madjar DD, Hardy S, et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. 2001;27(4):401-408.
(88.) Friedman PM, Friedman RH, Jiang SB, Nouri K, Amonette R, Robins P. Microcystic adnexal carcinoma: collaborative series review and update. J Am Acad Dermatol. 1999;41(2, pt 1):225-231.
(89.) Crowson AN, Magro CM, Mihm MC. Malignant adnexal neoplasms. Mod Pathol. 2006;19)(suppl 2):S93-S126.
(90.) Danialan R, Mutyambizi K, Aung P, Prieto VG, Ivan D. Challenges in the diagnosis of cutaneous adnexal tumours. J Clin Pathol. 2015;68(12):992-1002.
(91.) Krahl D, Sellheyer K. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma. J Cutan Pathol. 2007;34(10):782-787.
(92.) Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M. Microcystic adnexal carcinoma: an immunohistochemical reappraisal. Mod Pathol. 2008; 21(2):178-185.
(93.) Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the eyelids: personal experience with 60 cases. Ophthalmology. 2004;111 (12):2151-2157.
(94.) Callahan EF, AppertDL, Roenigk RK, Bartley GB. Sebaceous carcinoma of the eyelid: a review of 14 cases. Dermatol Surg. 2004;30(8):1164-1168.
(95.) Candelario NM, Sanchez JE, Sanchez JL, Martin-Garcia RF, Rochet NM. Extraocular sebaceous carcinoma--a clinicopathologic reassessment. Am J Dermatopathol. 2016;38(11):809-812.
(96.) Plaza JA, Mackinnon A, Carrillo L, Prieto VG, Sangueza M, Suster S. Role of immunohistochemistry in the diagnosis of sebaceous carcinoma: a clinicopathologic and immunohistochemical study. Am J Dermatopathol. 2015;37(11): 809-821.
(97.) Shields JA, Demirci H, Marr BP, Eagle RC Jr, Shields CL. Sebaceous carcinoma of the ocular region: a review. Surv Ophthalmol. 2005;50(2):103-122.
(98.) Kyllo RL, Brady Kl, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg. 2015;41(1):1-15.
(99.) Misago N, Suse T, Uemura T, Narisawa Y. Basal cell carcinoma with sebaceous differentiation. Am J Dermatopathol. 2004;26(4):298-303.
(100.) Abreu Velez A, Howard M, Kim J, Googe P. Markers for sebaceoma show a spectrum of cell cycle regulators, tumor suppressor genes, and oncogenes. N Am J Med Sci. 2015;7(6):275-280.
(101.) Bayer-Garner IB, Givens V, Smoller B. Immunohistochemical staining for androgen receptors: a sensitive marker of sebaceous differentiation. Am J Dermatopathol. 1999;21(5):426-431.
(102.) Muthusamy K, Halbert G, Roberts F. Immunohistochemical staining for adipophilin, perilipin and TIP47. J Clin Pathol. 2006;59(11):1166-1170.
(103.) Prieto-Granada C, Rodriguez-Waitkus P. Sebaceous carcinoma of the eyelid. Cancer Control. 2016;23(2):126-132.
(104.) Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States [published correction appears in I Am Acad Dermatol. 2004; 50(5):733].J Am Acad Dermatol. 2003;49(5):832-841.
(105.) Pulitzer MP, Amin BD, Busam KJ. Merkel cell carcinoma: review. Adv Anat Pathol. 2009;16(3):135-144.
(106.) Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol. 2005;23(10):2300-2309.
(107.) Ball NJ, Tanhuanco-Kho G. Merkel cell carcinoma frequently shows histologic features of basal cell carcinoma: a study of 30 cases. J Cutan Pathol. 2007;34(8):612-619.
(108.) Plaza JA, Suster S. The Toker tumor: spectrum of morphologic features in primary neuroendocrine carcinomas of the skin (Merkel cell carcinoma). Ann Diagn Pathol. 2006;10(6):376-385.
(109.) Brown HA, Sawyer DM, Woo T. Intraepidermal Merkel cell carcinoma with no dermal involvement. Am J Dermatopathol. 2000;22(1):65-69.
(110.) Llombart B, Monteagudo C, Lopez-Guerrero JA, et al. Clinicopathological and immunohistochemical analysis of 20 cases of Merkel cell carcinoma in search of prognostic markers. Histopathology. 2005;46(6):622-634.
(111.) D'Agostino M, Cinelli C, Willard R, Hofmann J, Jellinek N, RobinsonBostom L. Epidermotropic Merkel cell carcinoma: a case series with histopathologic examination. I Am Acad Dermatol. 2010;62(3):463-468.
(112.) de Faria J. Basal cell carcinoma of the skin with areas of squamous cell carcinoma: a basosquamous cell carcinoma? J Clin Pathol. 1985;38(11):1273-1277.
(113.) Skelton HG, Smith KJ, Hitchcock CL, McCarthy WF, Lupton GP, Graham JH. Merkel cell carcinoma: analysis ofclinical, histologic, and immunohistologic features of 132 cases with relation to survival. J Am Acad Dermatol. 1997;37(5 Pt 1):734-739.
(114.) Yang DT, Holden JA, Florell SR. CD117, CK20, TTF-1, and DNA topoisomerase II-a antigen expression in small cell tumors. J Cutan Pathol. 2004; 31(3):254-261.
(115.) Tang CK, Toker C, Nedwich A, Zaman AN. Unusual cutaneous carcinoma with features of small cell (oat cell-like) and squamous cell carcinomas: a variant of malignant Merkel cell neoplasm. Am J Dermatopathol. 1982;4(6):537-548.
(116.) Warner TF, Uno H, Hafez GR, et al. Merkel cells and Merkel cell tumors: ultrastructure, immunocytochemistry and review of the literature. Cancer. 1983; 52(2):238-245.
(117.) Jensen K, Kohler S, Rouse RV. Cytokeratin staining in Merkel cell carcinoma: an immunohistochemical study of cytokeratins 5/6, 7, 17, and 20. Appl Immunohistochem Mol Morphol. 2000;8(4):310-315.
(118.) Coursaget P, Samimi M, Nicol JT, Gardair C, Touze A. Human Merkel cell polyomavirus: virological background and clinical implications. APMIS. 2013; 121(8):755-769.
(119.) George E, Swanson PE, Wick MR. Neuroendocrine differentiation in basal cell carcinoma: an immunohistochemical study. Am J Dermatopathol. 1989; 11(2):131-135.
(120.) Visscher D, Cooper PH, Zarbo RJ, Crissman JD. Cutaneous neuroendocrine (Merkel cell) carcinoma: an immunophenotypic, clinicopathologic, and flow cytometric study. Mod Pathol. 1989;2(4):331-338.
(121.) Dessauvagie BF, Wood BA. CD117 and CD43 are useful adjuncts in the distinction of adenoid cystic carcinoma from adenoid basal cell carcinoma. Pathology. 2015;47(2):130-133.
(122.) Pletneva MA, Andea A, Palanisamy N, et al. Clear cell melanoma: a cutaneous clear cell malignancy. Arch Pathol Lab Med. 2014;138(10):1328-1336.
Lauren M. Stanoszek, MD, PhD; Grace Y. Wang, MD; Paul W. Harms, MD, PhD
Accepted for publication May 23, 2017.
From the Departments of Pathology (Drs Stanoszek, Wang, and Harms) and Dermatology (Dr Harms), University of Michigan Medical School, Ann Arbor. Drs Stanoszek and Wang contributed equally.
The authors have no relevant financial interest in the products or companies described in this article.
Presented in part at the New Frontiers in Pathology meeting; University of Michigan; October 13, 2016; Ann Arbor, Michigan.
Reprints: Paul W. Harms, MD, PhD, Department of Pathology, University of Michigan, 3261 Medical Science I, 1301 Catherine St, Ann Arbor, MI 48109-5602 (email: firstname.lastname@example.org).
Please Note: Illustration(s) are not available due to copyright restrictions
Caption: Figure 1. Basal cell carcinoma (BCC). A, Superficial BCC displaying small basaloid nodules with prominent peripheral palisading, extending from the base of the epidermis into the papillary dermis. B, Nodular (circumscribed) BCC displaying large, well-defined dermal nodules. C, Basaloid cells with peripheral nuclear palisading and clefting between tumor and stroma. Characteristic BCC stroma displays inflammation, fibrosis, prominent large fibroblasts, and increased mucin. D, Aggressive (infiltrating) BCC displaying angulated strands of tumor cells in mucinous stroma. E, Micronodular BCC with small, round, and infiltrative nodules. F, Morpheaform BCC may be composed of deceptively bland tumor nodules and strands within sclerotic stroma. G, Fibroepithelioma of Pinkus, with thin anastomosing epithelial cords in a myxoid stroma. H, Focal mitotic activity and cleft retraction in fibroepithelioma of Pinkus (hematoxylin-eosin, original magnifications X200 [A and C], X20 [B, D, E, and F], X10 [G], and X23 [H]).
Caption: Figure 2. Follicular induction (FI) in dermatofibroma (DF). A, Basaloid bud with peripheral, palisading and clefting, adjacent to epidermal hyperplasia. Fibrohistiocytic cells are visible in the underlying dermis. B, Larger nodules may form in FI. C, Follicular differentiation in FI may take the form of a papillary mesenchymal body. D, Scanning appearance of a rare DF-basal cell carcinoma (BCC) collision tumor. E, The DF in this collision tumor displays FI. F, Adjacent BCC in the collision tumor (hematoxylin-eosin, original magnifications X200 [A through C, E, and F] and X10 [D]).
Caption: Figure 3. A, Trichoblastoma, displaying bland basaloid cells in follicular stroma. B, Trichoepithelioma at scanning magnification, displaying racemiform patterning of basaloid cells in a follicular stroma. C, Trichoepithelioma with papillary mesenchymal body (arrowhead) and calcification. D, Desmoplastic trichoepithelioma displaying strands of bland basaloid cells with horn-cyst formation, in a sclerotic stroma. E, Cytokeratin 20 staining highlights Merkel cells (arrowheads) colonizing desmoplastic trichoepithelioma (hematoxylin-eosin, original magnifications X100 [A], X10 [B], X140 [C], and X400 [D]; original magnification X400 [E]).
Caption: Figure 4. A, Basaloid follicular hamartoma, displaying anastomosing basaloid strands with horn cysts and numerous epidermal connections. B, Small cells without atypia or mitotic activity in basaloid follicular hamartoma. C, Infundibulocystic basal cell carcinoma (BCC) displays similar architecture with anastomosing strands and horn cysts but is associated with myxoinflammatory stroma. D, Mitotic activity and cytologic atypia in infundibulocystic BCC (hematoxylin-eosin, original magnifications X20 [A], X110 [B], X60 [C], and X400 [D]).
Caption: Figure 5. Tumor of the follicular infundibulum displaying platelike growth in the superficial dermis, with numerous connections to the overlying epidermis (hematoxylin-eosin, original magnification X100).
Caption: Figure 6. Microcystic adnexal carcinoma. A, Horn cysts in the superficial portion of the tumor give way to small strands with ductal differentiation in the deeper aspect of the tumor. B, Subtle infiltrative clusters of tumor cells with ductal differentiation in the deep aspect of a microcystic adnexal carcinoma (hematoxylin-eosin, original magnifications X6 [A] and X200 [B]).
Caption: Figure 7. A, Sebaceous carcinoma. Cells displaying microvesiculated clear cytoplasm consistent with sebaceous differentiation, intermingled with undifferentiated, malignant basaloid cells. B, Basal cell carcinoma (BCC) with sebaceous differentiation displaying scattered sebocytes. Mucinous stroma and subtle peripheral palisading is evident. Other areas of this tumor displayed more classic findings of BCC (hematoxylin-eosin, original magnifications X200 [A] and X100 [B]).
Caption: Figure 8. Merkel cell carcinoma (MCC). A, Scanning magnification typically demonstrates a large, blue tumor in the dermis. B, Round cells with neuroendocrine chromatin, minimal cytoplasm, and numerous mitoses. C, Stromal mucin and cleft retraction may be prominent. Note the absence of prominent fibroblasts and fibrosis mingled with mucin that would be seen in characteristic basal cell carcinoma (BCC) stroma. D, Cytokeratin 20 displaying a dotlike paranuclear staining pattern in MCC (hematoxylin-eosin, original magnifications X10 [A], X400 [B and D], and X200 [C]).
Histologic Mimics of Basal Cell Carcinoma (BCC) Potential Distinctive Diagnostic Entity Overlapping Features Morphologic Features With BCC From BCC Nonneoplastic epidermal changes Follicular induction Superficial budlike, Presence of over dermatofibroma basaloid, epidermal underlying proliferation; dermatofibroma; peripheral evidence of palisading (focal) follicular retraction artifact differentiation (eg, papillary mesenchymal bodies); background epidermal hyperplasia;small nuclei;no atypia, increased mitotic figures, or apoptotic bodies. Benign follicular tumors Benign, hair-germ Basaloid Well-circumscribed, tumors cells;peripheral symmetrical; (trichoepithelioma, palisading;mucin delicate stroma with trichoblastoma) deposition within small spindled tumor cells; papillary nodules;apoptotic mesenchymal bodies bodies;connection to (rare in BCC) epidermis (less common than in BCC) Horn cysts and associated giant cell reaction (rare in BCC); mitotically inactive;no tumor necrosis, no cytologic atypia; no stromal mucin or peripheral clefting Basaloid follicular Superficial, dermal Cystic structures hamartoma proliferation of (uncommon in BCC, interconnecting except basaloid cells; infundibulocystic connection to the type);mitotically epidermis inactive;no tumor necrosis, no cytologic atypia;no myxoinflammatory stroma or peripheral clefting Tumor of follicular Peripheral Mitotically infundibulum palisading;may have inactive;no basaloid morphology; cytologic atypia, no connection to myxoid inflammatory epidermis stroma, no stroma to tumor clefting Sclerosing basaloid neoplasms (a) DTE Irregular nests Granulomatous (comma-shaped or inflammation "paisley tie") of associated with horn small, basaloid cysts; mitotically cells;desmoplastic inactive;no tumor stroma necrosis, no cytologic atypia; no myxoinflammatory stroma or peripheral clefting;horn cysts and associated giant cell reaction (rare in BCC) Syringoma Irregular nests Well circumscribed (comma-shaped or ;superficial; "paisley tie") of ductal small, basaloid differentiation; cells;sclerotic mitotically stroma inactive;no tumor necrosis, no cytologic atypia; no myxoinflammatory stroma or peripheral clefting Microcystic adnexal Infiltrative, Ductal carcinoma haphazardly differentiation with arranged, bland eosinophilic luminal basaloid cells; secretions; desmoplastic mitotically stroma;perineural inactive;no invasion (more myxoinflammatory common than in stroma or peripheral mBCC); horn cysts clefting (more common than in mBCC) Other cutaneous carcinomas Sebaceous carcinoma "Blue" tumor at Intraepidermal, (versus BCC with scanning pagetoid spread; no sebaceous magnification;oval peripheral differentiation) basaloid clefting;may be nuclei;mitotic evidence of activity;tumor sebaceous, lobular necrosis;may show architecture;often evidence of relatively greater palisading cytologic atypia and less basaloid morphology compared with BCC Squamous cell Squamous Intraepidermal, carcinoma differentiation pagetoid spread; no peripheral palisading; myxoinflammatory stroma; peripheral clefting Merkel cell "Blue" tumor at Intraepidermal, carcinoma scanning pagetoid spread; magnification;may no-focal peripheral have nested, palisading; nodular, or homogenous salt- infiltrative growth and-pepper patterns;stromal chromatin;nuclear mucin; retraction molding; abundant artifact;tumor mitotic activity and necrosis;foci of necrosis squamous differentiation Diagnostic Entity Distinctive IHC From BCC Nonneoplastic epidermal changes Follicular induction [CK20.sup.+] over dermatofibroma (colonizing Merkel cells) Benign follicular tumors Benign, hair-germ [PHLDA1.sup.+]; tumors [CK20.sup.+] Merkel (trichoepithelioma, cells (may be trichoblastoma) sparse);[AR.sup.-] (BCC is frequently [AR.sup.+], although this expression is typically focal); [CD10.sup.+] (stroma);[BCL2.sup.+] (peripheral, not diffuse)--mixed reports on diagnostic utility Basaloid follicular [CD34.sup.+] hamartoma (outlines tumor islands); [CK20.sup.+] (Merkel cells)--utility has been debated for distinction from infundibulocystic BCC Tumor of follicular [BCL2.sup.-]; Ber- infundibulum [EP4.sup.-]; [CK20.sup.+] (colonizing Merkel cells); elastin stain--elastin fiber network at base Sclerosing basaloid neoplasms (a) DTE [PHLDA1.sup.+]; [CK20.sup.+] Merkel cells (may be sparse);[AR.sup.-] (although AR expression may be focal in BCC) Syringoma [CD200.sup.+]; claudin [4.sup.+]; [EMA.sup.+]; and [CEA.sup.+] (highlight lumina) Microcystic adnexal [CK15.sup.+]; carcinoma [EMA.sup.+]; and [CEA.sup.+] (highlight lumina);mixed reports regarding Ber-EP4 in MAC Other cutaneous carcinomas Sebaceous carcinoma Diffuse [AR.sup.+] (versus BCC with (versus focally sebaceous positive in differentiation) BCC);low-molecular- weight [CK.sup.+]; [EMA.sup.+]; Ber- [EP4.sup.-] Squamous cell Ber-[EP4.sup.-] carcinoma (also absent in squamous areas of BCC); [EMA.sup.+] (may be expressed in squamous areas of BCC) Merkel cell [CK20.sup.+] carcinoma (paranuclear, dotlike pattern); neuroendocrine markers are not reliable for this distinction Abbreviations: AR, androgen receptor;CEA, carcinoembryonic antigen; DTE, desmoplastic trichoepithelioma; EMA, epithelial membrane antigen; IHC, immunohistochemistry;MAC, microcystic adnexal carcinoma. (a) Potential overlap with morpheaform BCC.
|Printer friendly Cite/link Email Feedback|
|Author:||Stanoszek, Lauren M.; Wang, Grace Y.; Harms, Paul W.|
|Publication:||Archives of Pathology & Laboratory Medicine|
|Date:||Nov 1, 2017|
|Previous Article:||Myxoinflammatory Fibroblastic Sarcoma: Review and Update.|
|Next Article:||Primary Cutaneous Acral [CD8.sup.+] T-Cell Lymphoma.|